BloodScan Biotech Inc., founded in 2023, is a biotechnology company focused on innovating and applying liquid biopsy technology. Established and technology-transferred by a research team from the University of Michigan, the company aims to set a new global standard in the field of liquid biopsy, with the primary goal of overcoming cancer.
The company’s core technology, Labyrinth One—Automated CTC Enrichment System, features innovative designs that significantly enhance the purity, efficiency, and viability of CTC extraction from blood samples. This advancement has a profound impact on cancer diagnosis, monitoring, and personalized medicine, with the potential to achieve breakthrough progress in cancer care.
BloodScan Biotech's mission is to integrate industry, academia, and research efforts to drive improvements throughout the entire cancer diagnosis and treatment cycle using cutting-edge technology, ultimately aiming to transform cancer care.
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Bloodscan Biotech Inc. Questions
Bloodscan Biotech Inc.'s website is https://www.bloodscanbiotech.com/
Bloodscan Biotech Inc.'s LinkedIn profile is https://www.linkedin.com/company/bloodscanbiotech
Bloodscan Biotech Inc. has
2 employees.
View email and phone details for 2
employees at Bloodscan Biotech Inc..
Bloodscan Biotech Inc.'s industry is
Biotechnology Research
Bloodscan Biotech Inc.'s top competitors are
University Of Michigan Biointerfaces Institute,
Visera Technologies,
Acrocyte Therapeutics,
Cytoarm｜bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment,
Dentscape,
Checkorphan,
Precisemab Biotech Co., Ltd.,
Novascope,
Visera,
Abvc Biopharma.
Bloodscan Biotech Inc.'s categories are Biotechnology Research
Bloodscan Biotech Inc.'s founding year is 2023
